<DOC>
	<DOCNO>NCT02197598</DOCNO>
	<brief_summary>The purpose study explore treatment effect Selincro alcohol dependent patient liver impairment .</brief_summary>
	<brief_title>Treatment Patients Suffering Alcohol Dependence Impaired Liver Function With Selincro® As-needed Use</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>The patient alcohol dependence , diagnose screen accord DSMIVTR™ The patient average alcohol consumption , least , high drinking risk level ( &gt; 60 g alcohol/day men &gt; 40 g alcohol/day woman ) 4 week precede Screening Visit period Screening Inclusion Visits ( , Screening Period ) The patient liver impairment define elevate liver stiffness elevate liver enzyme Screening Visit ( criterion fulfil ) : liver stiffness ( LS ) measure Fibroscan &gt; 6 kPa , elevate transaminase ( AST ALT ) . Transaminase level 5 time upper limit reference range γGT level 10 time upper limit reference range allow . At discretion investigator , transaminase level &gt; 5 time upper limit reference range γGT &gt; 10 time upper limit reference range allow consider habitual patient , either confirm patient record repeat measurement Screening Period The patient breath alcohol concentration ( BrAC ) &lt; 0.02 % Screening Visit . The patient provide stable address telephone number The patient man woman , age ≥ 18 year The patient BMI≤30 kg/m2 The patient psychiatric disorder Axis I disorder ( DSMIVTR™ criterion ) , establish primary diagnosis , alcohol dependence assess use Mini International Neuropsychiatric Interview ( MINI ) another diagnostic interview , way interfere ability patient take part study The patient report current use , test positive , drug abuse ( opiate , methadone , cocaine , amphetamine [ include ecstasy ] , barbiturate ) The patient severe liver impairment classify ChildPugh Score C The patient one clinical laboratory test value outside reference range , base blood urine sample take Screening Visit , potential risk patient 's safety , patient : Severe renal impairment ( eGFR &lt; 30 mL/min per 1.73 m2 ) , and/or Hypercholesterolemia serum cholesterol level &gt; 300 mg/dL , ( &gt; 7,758 mmol/L ) , and/or bilirubin &gt; 3 mg/dL ( 50 μmol/L ) The patient &lt; 6 heavy drinking day ( HDDs , define European Medicines Agency day alcohol consumption &gt; 60 g men &gt; 40 g woman ) 4 week precede Screening Visit The patient &gt; 5 consecutive abstinence day 4 week precede Screening Visit The patient recent history acute alcohol withdrawal syndrome ( include hallucination , seizure , delirium tremens ) Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>nalmefene , alcohol consumption , liver effect</keyword>
</DOC>